HIF1A and cancer: Network pharmacological screening showed that the active components of OI acted on the cancer pathway, P53 signaling pathway, HIF-1 signaling pathway, immune signaling and other key signaling pathways through the regulation of AKT1, TP53, CASP3, MMP9, IL-4, and so on, exerting anti-inflammatory, anticancer and antioxidant effects.